AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ's Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
Announced recently on the ASX, the collaboration extends a 2022 partnership that was focused on developing treatment for strawberry birthmarks in children.
Keloid scars, which can arise from any injury, often extend beyond the original wound, causing discomfort.
The new partnership aims to create the 'first effective topical solution' for this condition.
AFT Managing Director and CEO Hartley Atkinson highlighted the importance of the initiative, saying, "we are delighted to extend our collaboration, and this scar tissue program offers an attractive global commercial opportunity while helping patients with disfiguring keloid scars."
The program's initial phase will focus on finalising ingredients for the treatment, followed by a comprehensive development process that includes manufacturing, toxicology work, and clinical trials.
Dr Clint Gray, Director of the Gillies McIndoe Research Institute, added, "current treatment options for keloid and hypertrophic scarring are limited and can be invasive, leading to further scarring".
"Our topical treatment aims to prevent the excessive collagen buildup that causes these scars.
"A topical solution offers a less invasive option and the convenience of self-application." JG
The above article was sent to subscribers in Pharmacy Daily's issue from 07 May 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 May 24
